Cyclacel Pharmaceuticals, Inc.

360 articles with Cyclacel Pharmaceuticals, Inc.

• Cyclacel Announces Dosing of First Patient in Phase 1/2 Study of Oral Fadraciclib in Patients With Advanced Solid Tumors and Aggressive Lymphomas

  7/13/2021

  Cyclacel Pharmaceuticals, Inc., a biopharmaceutical company developing innovative medicines based on cancer cell biology, announced dosing of the first patient in the Company’s multi-cohort Phase 1/2 study of oral fadraciclib in patients with advanced solid tumors.

• Cyclacel Pharmaceuticals to Present at Ladenburg Thalmann’s Virtual 2021 Healthcare Conference

  7/7/2021

  Cyclacel Pharmaceuticals, Inc., a biopharmaceutical company developing innovative medicines based on cancer cell biology, announced that it will participate in the Ladenburg Thalmann’s Virtual 2021 Healthcare Conference held July 13-14, 2021.

• Cyclacel Pharmaceuticals Reports First Quarter 2021 Financial Results

  5/12/2021

  Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, today reported its financial results for the first quarter 2021 and business highlights, including an update on its progress with fadraciclib and CYC140, Cyclacel's novel CDK2/9 and PLK1 inhibitors, respectively.

• Cyclacel Pharmaceuticals to Release First Quarter 2021 Financial Results and Provide Business Update

  5/5/2021

  Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, will announce first quarter financial results and provide a business update on Wednesday, May 12, 2021. The company will host a conference call and live webcast at 4:30 p.m. Eastern Daylight Time on the same day.

• Cyclacel Pharmaceuticals Announces Closing of $14.5 Million Underwritten Public Offering and Full Exercise of Over-Allotment Option

  3/16/2021

  Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, today announced the closing of its previously announced underwritten public offering of 2,078,214 shares of its common stock, offered at a price of $7.00 to the public,

• Cyclacel to Present at the Oppenheimer 31st Annual Healthcare Conference

  3/15/2021

  Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, today announced that the Company will present at the Oppenheimer 31 st  Annual Healthcare Conference, a virtual event, on Thursday, March 18, 2021 at 9:20 AM (EDT).

• Cyclacel Pharmaceuticals Prices $12.65 Million Underwritten Public Offering of Common Stock

  3/12/2021

  Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, today announced the pricing of an underwritten public offering of 1,807,143 shares of its common stock, offered at a price of $7.00 to the public. Additionally, the Company has granted the underwriters a 30-day option to purchase up to an additional 271,071

• Cyclacel Pharmaceuticals Announces Proposed Public Offering of Common Stock

  3/11/2021

  Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, announced today that it intends to offer shares of its common stock for sale in an underwritten public offering

• Cyclacel Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial ResultsConference Call Scheduled February 25, 2021 at 4:30 p.m. EDT

  2/25/2021

  Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company") a biopharmaceutical company developing innovative medicines based on cancer cell biology, today reported its financial results and business highlights for the fourth quarter and full year ended December 31, 2020.

• Cyclacel Pharmaceuticals to Release Fourth Quarter and Full Year 2020 Financial Results

  2/19/2021

  Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, will announce fourth quarter and full year 2020 financial results on Thursday, February 25, 2021.

• Cyclacel Pharmaceuticals Announces Presentation at 2021 BIO CEO & Investor Digital Conference

  2/10/2021

  Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, today announced that the Company will present at the 2021 BIO CEO & Investor Digital Conference

• Cyclacel Pharmaceuticals Reviews 2020 Achievements and Announces Key Business Objectives for 2021

  1/11/2021

  Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, today provided a business update reviewing 2020 achievements and outlining the Company’s key business objectives for 2021

• Cyclacel Pharmaceuticals to Present at Biotech Showcase™ Digital 2021

  12/30/2020

  Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, today announced that the Company will present at Biotech Showcase™ Digital 2021. The conference is taking place online between January 11-15 and will feature prerecorded sessions of company presentations. Spiro Rombotis, President & Chief Executive Office

• Cyclacel Pharmaceuticals Announces at-the-market $7 Million Strategic Investment by Fundamental Investor Acorn Bioventures

  12/22/2020

  - Strategic investment from single biotech-focused institutional investor - - Enables clinical development of both fadraciclib and CYC140 in hematological malignancies and solid tumors -

• Cyclacel Pharmaceuticals Announces That Brian Schwartz, M.D. Was Elected to Its Board of DirectorsFormer CMO & Head of R&D of ArQule joins the Board

  12/21/2020

  Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, today announced the election of Brian Schwartz, M.D., to its Board of Directors.

• Cyclacel Pharmaceuticals Reports Third Quarter 2020 Financial Results- Conference Call Scheduled November 11, 2020 at 4:30 p.m. ET -

  11/11/2020

  Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, today reported its financial results for the third quarter 2020 and certain business highlights. The Company's net loss applicable to common shareholders for the three months ended September 30, 2020 was $2.3 million. As of September 30, 2020, cash and cash

• Cyclacel Pharmaceuticals to Release Third Quarter 2020 Financial Results

  11/5/2020

  Cyclacel Pharmaceuticals, Inc., a biopharmaceutical company developing innovative medicines based on cancer cell biology, will announce third quarter 2020 financial results on Wednesday, November 11, 2020.

• 

  BioSpace Movers & Shakers, Oct. 30

  10/30/2020

  Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers.

• Cyclacel Presents Phase 1 Clinical Data Showing Safety, Anti-Tumor Activity and Good Oral Bioavailability of Fadraciclib in Patients With Advanced Solid Tumors at the EORTC-NCI-AACR Symposium 2020

  10/26/2020

  A patient with MCL1 amplified endometrial cancer achieved partial response (PR) with 92% target tumor shrinkage on singe agent fadraciclib

• Cyclacel Pharmaceuticals Announces Appointment of Mark Kirschbaum, M.D., as Chief Medical Officer

  10/23/2020

  Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC, Nasdaq:CYCCP) ("Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, announced the appointment of Mark Kirschbaum, M.D. as Senior Vice President & Chief Medical Officer (CMO). Dr. Kirschbaum is a highly experienced hematologist/oncologist with over 30 years of experience in molecular medicine, new drug development, clinical